A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer.

Trial Profile

A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Dasatinib; Gemcitabine
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 22 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Planned End Date changed from 1 Jun 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top